Glucagon Market Size, Share & Trends Analysis Report By Product (Inject Glucagon, Nasal Glucagon.), By Applications (Emergency Use, General Use), By End Use, By Region, and Segment Forecasts - 2035

GLUCAGON MARKET OVERVIEW

glucagon market Size was estimated at 625.91 USD million in 2025, The industry is projected to grow from 664.09 USD million in 2026 to 793.18 USD million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.1% during the forecast period 2026 - 2035.

The glucagon market is pushed by using the growing prevalence of diabetes and hypoglycemia management. Glucagon, a hormone used to elevate blood glucose ranges, is crucial for emergency remedy in insulin-precipitated hypoglycemia cases. Market growth is supported via the growing attention of diabetes control, improvements in healthcare infrastructure, and improved get right of entry to to treatment. Key gamers are centered on product innovation, inclusive of nasal glucagon formulations, making management less complicated, especially for non-clinical employees. Additionally, increasing R&D sports and medical trials for glucagon-based totally treatments extend its applications beyond diabetes, such as in diagnostic imaging techniques and endocrine issues. North America holds a sizeable market share due to high diabetes prevalence, advanced healthcare structures, and favorable compensation regulations. However, the marketplace faces demanding situations like stringent regulatory requirements and capability side outcomes, that can sluggish growth. Overall, the glucagon market is poised for mild growth with non-stop advancements in treatment alternatives.

The United States is the largest market for glucagon, driven by the high prevalence of diabetes, increasing awareness of severe hypoglycemia management, and widespread availability of emergency rescue therapies. Glucagon is used to rapidly raise blood glucose levels in individuals experiencing severe hypoglycemia and is increasingly available in ready-to-use injectable and nasal formulations. Growing adoption of continuous glucose monitoring systems, insulin pump therapy, and comprehensive diabetes management programs is supporting demand for advanced glucagon products. Continued investments in biopharmaceutical innovation, user-friendly drug delivery systems, and emergency diabetes care continue to strengthen the U.S. glucagon market.

• • 

    Download Free sample to learn more about this report.

KEY FINDINGS

• Market Size and Growth: The Glucagon Market size was USD 589.92 Million in 2024, is projected to grow to USD 613.84 Million by 2025 and exceed USD 704.59 Million by 2033, with a CAGR of 6.1%

• Key Market Driver: The rising incidence of hypoglycemia is pushing demand—over 30% of insulin-treated diabetics experience at least one severe hypoglycemic episode annually, according to global health estimates.

• Major Market Restraint: Short shelf life of reconstituted glucagon remains a problem—most emergency kits must be used within 24 hours once mixed, creating logistical and storage challenges for clinics and patients.

• Emerging Trends: Ready-to-use nasal glucagon is gaining momentum—FDA-approved intranasal formulations reduce prep time and improve usability in emergencies, with adoption up 18% year-on-year since 2022.

• Regional Leadership: North America dominates the space, accounting for nearly 45% of global usage in 2023, fueled by strong insurance coverage and robust diabetes management infrastructure.

• Competitive Landscape: Fewer than 10 major players dominate the industry, with Eli Lilly and Zealand Pharma leading innovations in both injectable and intranasal delivery formats.

• Market Segmentation: Emergency kits account for more than 60% of global demand, driven by increased use in public and private healthcare settings for diabetic emergencies.

• Recent Development: In late 2023, Xeris Pharmaceuticals launched Gvoke HypoPen in additional European markets—expanding its auto-injector presence across 7 countries within a year.

COVID-19 IMPACT

"Glucagon Industry Had a Negative Effect Due to Disrupted Delivery Chains During COVID-19 Pandemic"

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic had a mixed impact on the worldwide glucagon market. On one hand, disruptions in supply chains and healthcare sources not on time production and distribution, restricting marketplace boom. Many sufferers faced confined get right of entry to hospitals and clinics, impacting ordinary diabetes and hypoglycemia control. However, the pandemic additionally heightened awareness round emergency preparedness in healthcare, encouraging higher call for crucial remedies like glucagon. Increased telemedicine adoption facilitated far off diabetes control, probably boosting glucagon use for hypoglycemia in home settings. Overall, even as COVID-19 posed challenges, it also underscored the importance of reachable and emergency-geared up glucagon merchandise.

RUSSIA-UKRAINE WAR IMPACT

"Glucagon ""Market Had a Negative Effects Because War Disrupted Delivery Chains & Increased Production Costs During the Russia-Ukraine War"

The Russia-Ukraine war has heightened global concerns, affecting Glucagon market share impacting the glucagon marketplace via disrupted deliver chains and rising manufacturing fees. Key substances and production processes have faced delays, in particular with Europe being a tremendous location for pharmaceutical exports. Economic sanctions on Russia have similarly strained trade routes and brought about improved fuel and transportation fees, which elevate the general expenses for glucagon manufacturing and distribution. Additionally, market instability has induced some pharmaceutical groups to re-evaluate funding in rising treatments. These elements have created nearby marketplace imbalances and affected the affordability and accessibility of glucagon, mainly in close by and economically impacted regions.

LATEST TREND

"Growing Integration of Sustainable and Bio-degradable Products ""to Drive Market Growth"

A recent trend within the glucagon market is the shift in the direction of consumer-pleasant, non-injectable formulations, along with nasal glucagon and car-injectors. These advancements are designed to make glucagon administration simpler, specifically for non-clinical users for the duration of hypoglycemic emergencies. The nasal glucagon format, especially, has received a reputation because of its simplicity and effectiveness, lowering the need for conventional injections. Another trend is the elevated integration of digital health gear and telemedicine to assist diabetes control remotely. With the upward thrust of linked devices, sufferers and caregivers can reveal glucose ranges in real-time, figuring out and addressing hypoglycemic episodes quicker. Additionally, there is a focal point on increasing glucagon’s use in regions past diabetes, inclusive of positive diagnostic imaging procedures and for treating rare endocrine problems. Overall, the fashion closer to innovation in management, broader applications, and digital integration displays the market's response to growing patient desires and technological advancements.

• • 

    Download Free sample to learn more about this report.

GLUCAGON MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into Inject Glucagon, Nasal Glucagon.

• Inject Glucagon: Injectable glucagon is the conventional form used for treating severe hypoglycemia, usually administered via syringes or automobile-injectors. This shape remains widely utilized in hospitals and emergency settings wherein speedy intervention is required. While injectable glucagon is tremendously effective, its administration may be tough for non-clinical personnel in emergency conditions. However, its reliability and confirmed efficacy in dealing with hypoglycemia have stored it as a number one preference in glucagon remedies. Manufacturers are always enhancing injection gadgets, making them extra on hand and less intimidating for caregivers and patients alike, which facilitates maintain injection glucagon's market relevance.

• Nasal Glucagon: Nasal glucagon is a newer, non-invasive alternative that gets rid of the want for injections, making it less difficult for individuals without medical training to manage. This method allows speedy absorption via the nasal passages, supplying an efficient and much less intimidating option for dealing with hypoglycemia emergencies. Nasal glucagon has gained reputation for its ease of use, in particular in home and public settings wherein rapid response is important. Its comfort and effectiveness have driven its adoption, especially among sufferers and caregivers seeking out consumer-pleasant alternatives to injections. As awareness and availability boom, nasal glucagon is likely to seize a developing percentage of the marketplace, appealing to diverse demographic groups.

By Application

Based on Application, the global market can be categorized into Emergency Kits, General Use, Cardiogenic Shock, Diagnostic & Motility

• Emergency Kits: Glucagon emergency kits are essential for individuals with diabetes, enabling speedy remedy of excessive hypoglycemia. These kits are usually stocked with glucagon formulations and consist of injectables or nasal options. Designed for portability, they empower sufferers and caregivers to manipulate surprising hypoglycemic episodes efficiently. Emergency kits are often advocated by healthcare carriers for human beings at excessive threat of extreme hypoglycemia, making them famous in each non-public and institutional settings. The upward thrust in diabetes prevalence and greater emphasis on self-control have brought about elevated demand for those kits, with manufacturers specializing in compact, user-friendly designs.

• General Use: General use glucagon programs involve moderate hypoglycemia remedy in clinical and home settings. Often prescribed for normal control of blood sugar drops, these formulations are included into broader diabetes care plans. They cater to sufferers who want common, manageable doses to counter low glucose ranges without requiring emergency intervention. With a developing choice for self-care in diabetes control, well known use applications have end up vital. Healthcare companies and patients favor glucagon answers which can be smooth to administer and convenient, aligning with the increasing emphasis on at-domestic, non-invasive remedy alternatives in diabetes care.

• Diagnostic & Motility: In addition to diabetes remedy, glucagon has specific programs in diagnostic imaging, in particular for gastrointestinal processes. It is used to temporarily loosen up the belly and intestines, making an allowance for clearer imaging effects. The diagnostic & motility segment is steadily growing as greater healthcare providers apprehend the price of glucagon in improving imaging accuracy for situations related to digestive motility. As the call for advanced imaging strategies rises, so does using glucagon in these diagnostic procedures. This software broadens the hormone's use beyond hypoglycemia, giving it a treasured position in a wider range of scientific specialties.

• Cardiogenic Shock: Glucagon is once in a while used in treating cardiogenic shock, a intense condition where the coronary heart unexpectedly cannot pump enough blood to meet the body's needs. In those cases, glucagon acts as a fine inotropic agent, helping to stimulate the heart and improve cardiac output. Though a spot utility, glucagon’s ability function in treating cardiogenic shock is gaining interest in vital care settings. This off-label use has prompted studies into its efficacy and protection for cardiac patients, expanding the therapeutic panorama for glucagon. As clinical trials continue, cardiogenic surprise may represent a rising section for glucagon, albeit a specialized one.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

"Rising Prevalence of Diabetes and Hypoglycemia Awareness to Boost the Market"

A factor in the Glucagon market growth is the increase in Innovation in glucagon transport, such as nasal and auto-injectable formulations, is a key marketplace driving force. These more modern, non-invasive codecs make it less complicated for non-experts to manage glucagon, especially in high-strain situations. Improved convenience and simplicity of use have extended glucagon’s accessibility, attractive to a broader patient demographic and making glucagon a trendy addition to many diabetes management protocols. These advancements assist wider adoption and improve the marketplace’s boom trajectory.

"Growing Demand for Sustainable Solutions to Boost the Market "

With a increasing boom in diabetes cases worldwide, the call for glucagon has surged as a crucial emergency solution for hypoglycemia, a not unusual difficulty of diabetes treatment. Awareness campaigns and improved training round hypoglycemia control are riding extra patients and healthcare carriers to inventory and use glucagon for rapid intervention. Additionally, healthcare establishments and caregivers are emphasizing the significance of emergency preparedness, further boosting glucagon call for in each non-public and institutional settings.

Restraining Factor

"High Cost and Limited Accessibility to Potentially Impede Market Growth"

The price of glucagon merchandise remains a barrier, specifically for individuals without ok healthcare insurance. In many regions, affordability limits get admission to glucagon, affecting both availability and demand. Additionally, stringent regulatory requirements for glucagon formulations can cause behind schedule market entry of more recent, more modern alternatives, which in addition influences accessibility. These elements restrict the growth of glucagon’s attain, especially in decrease-profits regions, restraining typical marketplace increase.

Opportunity

"Expanding Applications Beyond Diabetes to Create Opportunity for The Product in The Market"

Glucagon’s programs are extending beyond diabetes to areas like diagnostic imaging and cardiogenic shock remedy, creating new possibilities. Its potential to facilitate motility in gastrointestinal methods has made it precious in diagnostic settings, wherein it aids in acquiring clearer imaging results. As studies maintains, glucagon may additionally find additional makes use of, opening doorways for manufacturers to capture untapped market segments and expand its relevance throughout scientific specialties, which can force future increase.

Challenge

"Regulatory Hurdles and Side Effects ""Could Be a Potential Challenge for Consumers"

Regulatory requirements for glucagon merchandise are stringent, as government prioritize affected person safety and efficacy. Compliance with those rules may be costly and time-eating for manufacturers, which may additionally postpone product approvals and marketplace entry. Furthermore, glucagon administration can bring about aspect outcomes like nausea and vomiting, potentially discouraging use amongst a few sufferers and caregivers. Managing these regulatory and scientific challenges whilst ensuring product protection stays a essential hurdle for organizations running inside the glucagon market.

• • 

    Download Free sampleto learn more about this report.

•  

GLUCAGON MARKET REGIONAL INSIGHTS

North America

United States Glucagon Market in North America led with the aid of the USA, holds a tremendous share because of high diabetes incidence and nicely hooked up healthcare infrastructure. The U.S. Market blessings from sturdy healthcare regulations, tremendous availability of emergency remedies, and a growing recognition on diabetes management. Additionally, advancements in non-invasive glucagon formulations, such as nasal sprays, have received traction, making emergency hypoglycemia treatment greater handy and convenient. Canada also contributes to marketplace boom, with an increasing demand for emergency glucagon kits and modern treatment solutions. Together, those factors solidify North America as a main place inside the glucagon market.

Europe

Europe’s glucagon market is expanding, driven by using the rising diabetic populace and growing cognizance of hypoglycemia control. Countries like Germany, the UK, and France lead in market share because of sturdy healthcare structures and favorable reimbursement rules. The European marketplace is also witnessing a shift in the direction of nasal and auto-injectable glucagon products, catering to patients in search of greater consumer-friendly alternatives. Regulatory assist for progressive drug transport answers further accelerates the adoption of recent formulations. Additionally, tasks promoting diabetes focus and management in numerous European countries have expanded demand, assisting marketplace increase and broadening glucagon's accessibility across the continent.

Asia

The glucagon marketplace in Asia is developing rapidly due to increasing diabetes instances, rising healthcare investments, and stepped forward get entry to emergency remedies. Countries like China, Japan, and India are seeing heightened demand for glucagon merchandise as diabetes becomes extra general in urbanized populations. However, value and restrained healthcare coverage remain challenges, especially in low- to middle-income areas. There is a growing hobby in introducing affordable, smooth-to-use glucagon formulations to fulfill various patient needs. As healthcare infrastructure strengthens and consciousness of diabetes management grows, the Asian glucagon marketplace is predicted to increase, with good sized potential for each existing and rising gamer.

KEY INDUSTRY PLAYER

"Key Industry Players Shaping the Market Through Innovation and Market Expansion"

Key industry players in the glucagon market are driving boom through innovation and strategic marketplace growth. Companies like Eli Lilly, Novo Nordisk, and Xeris Pharmaceuticals are at the leading edge, investing in superior glucagon formulations such as nasal sprays and auto-injectors, which beautify ease of use and accessibility for non-scientific users. These leaders are also expanding their reach throughout rising markets with the aid of developing fee-effective answers and organizing nearby partnerships. Additionally, they are involved in sizeable research and development efforts to discover glucagon’s potential packages past diabetes, which include in diagnostic strategies and cardiovascular aid, further solidifying their market impact.

List of Top Glucagon Companies

• Novo Nordisk – Denmark
• Eli Lilly - United States
• Fresenius Kabi - Germany

KEY INDUSTRY DEVELOPMENT

JUNE 2023: Key trends in the glucagon industry consist of advancements in non-injectable formulations and multiplied research into new therapeutic uses. Companies like Xeris Pharmaceuticals have added prepared-to-use, strong liquid glucagon, disposing of the need for reconstitution before management. Nasal glucagon, advanced by corporations including Eli Lilly, has revolutionized emergency hypoglycemia treatment by using supplying a needle-loose, person-pleasant choice. Additionally, medical trials are exploring glucagon’s applications in areas past hypoglycemia, including gastrointestinal imaging and cardiogenic surprise management. These innovations are improving affected person protection and convenience whilst broadening glucagon’s position in diverse medical settings, using persevered boom within the industry.

Five Recent Developments (2023-2025)

• Eli Lilly and Company (2023): Expanded patient support initiatives for its glucagon products while strengthening access to emergency hypoglycemia treatments through healthcare providers and pharmacies.
• Amphastar Pharmaceuticals (2024): Enhanced its glucagon product portfolio by increasing manufacturing capacity and improving supply chain capabilities to support growing market demand.
• Xeris Biopharma (2024): Expanded the availability of its ready-to-use liquid glucagon products with initiatives focused on improving emergency treatment accessibility and patient convenience.
• Novo Nordisk (2025): Strengthened its diabetes care portfolio through continued investment in next-generation glucagon-based therapies and integrated diabetes management solutions.
• Baqsimi (Eli Lilly) (2025): Expanded educational and awareness programs supporting the use of nasal glucagon for the emergency treatment of severe hypoglycemia in people with diabetes.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis considers both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.